StockData

Anika Therapeutics vs Neuronetics

ANIK and STIM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIK and STIM compare

Anika Therapeutics is the larger company, worth 1.8 times as much as Neuronetics ($172M against $97.5M).

Neuronetics grew revenue faster over the last twelve months (39.6% versus 5.3% for Anika Therapeutics).

Anika Therapeutics keeps more of each dollar of sales as profit, with a net margin of −3.1% compared with −19.6% at Neuronetics.

Anika Therapeutics scores higher on the StockData Score (11 against 4 for Neuronetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIKSTIM
Size and price
Market cap$172M$97.5M
Share price$12.85$1.28
Change, 1 year28.6%−35.7%
Change, 5 years−67.6%−68.9%
Beta (5Y)1.061.93
Employees235658
StockData Score
Total score11 (better)4
Valuation score1 (better)0
Growth score12 (better)
Performance score3 (better)1
Health score6 (better)1
Dividend score00
Valuation
P/S1.4×0.6× (better)
P/B1.3× (better)5.5×
EV/EBITDA267×–
P/FCF306×–
FCF yield0.33% (better)−11.6%
Growth
Revenue growth (TTM)5.3%39.6% (better)
Revenue growth, 5Y average−2.9%24.8% (better)
Profitability
Gross margin62.2% (better)49.1%
Operating margin−4.2% (better)−14.7%
Net margin−3.1% (better)−19.6%
FCF margin0.47% (better)−7.3%
Return on equity−2.7% (better)−135%
Return on invested capital−4.8% (better)−27.4%
Financial health
Debt / equity0.003.45 (better)
Interest coverage–−2.6×
Current ratio4.48 (better)1.88
Altman Z-score3.75 (better)−3.67
Piotroski F-score6 (better)4
Dividends and buybacks
Buyback yield8.8%–
Shareholder yield8.8% (better)0.00%
Ownership
Held by institutions91.9%48.8%
Held by insiders16.9%52.8%
Insider net buying, 12 months$264K (better)$170K
Short interest, % of float2.9%18.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.